Clinical Trial Search

Primary: Change in Radiation Esophagitis-related Pain at 4 Weeks as Measured by the Numerical Rating Pain Scale for Pain on Swallowing (NRPS) — 1; 1; 1 units on a scale — p=0.92

Primary: Bleeding Complication — 0; 2; 0; 2 participants

Primary: Cmax of Oxymetazoline — 1.45; 2.05 ng/mL

Primary: Number of Participants With On-Treatment Adverse Events (AEs), AEs Led to Withdrawal, and Serious Adverse Events (SAEs) — 249; 53; 80 Participants

Primary: Percentage of Participants in Arms A, B and C With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) — 96.6; 100.0; 93.4 percentage of participants

Primary: Part 3: Change in Diurnal IOP (Averaged Over 8 AM, 10 AM, Noon, 4 PM, and 8 PM) From Baseline to Day 8 — -0.6; -1.1 mmHg

Primary: Percentage of Successful First Attempt Lumbar Punctures in the Ultrasound-assisted Group as Compared to the Non-ultrasound Assisted Group — 58; 31 percent success

Primary: Perioperative Sleep Efficiency — 20; -55 minutes

Primary: Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) - All Participants — 3.3; 2.1 Months — p=0.41648

Primary: To Determine Whether, in Comparison to TT II, the Median EFS Can be Increased From 4.8 Years to 6.2 Years, Which Represents an Increase in Median EFS of Approximately 30%

Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) — 93.9 percentage of participants

Primary: Days of Treatment With Opioid Medication — 13.9; 22.9 days

Primary: Ocular Itching at Duration of Action (16 Hours Post-dose) — 1.91; 2.00; 1.65; 2.48 units on a scale

Primary: Time-weighted Sum of Pain Intensity Difference Scores on 11-Point Numerical Scale From 0 to 8 Hours Post-dose (SPID11 [0-8]) — 4.1; 34.3; 28.9; 19.4 units on a scale…

Primary: Composite of Incidence of Death, Reinfarction, Unstable Angina Pectoris, Stroke, Unplanned Rehospitalization, Repeat Target Vessel Revascularization and Stent Thrombosis…